Supramolecular alleviation of cardiotoxicity ...
Document type :
Article dans une revue scientifique
DOI :
Title :
Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor
Author(s) :
Yang, Xue [Auteur]
Huang, Qiaoxian [Auteur]
Bardelang, David [Auteur]
Institut de Chimie Radicalaire [ICR]
Wang, Chunming [Auteur]
Savoirs, Textes, Langage (STL) - UMR 8163 [STL]
Lee, Simon M. Y. [Auteur]
Wang, Ruibing [Auteur]
Huang, Qiaoxian [Auteur]
Bardelang, David [Auteur]
Institut de Chimie Radicalaire [ICR]
Wang, Chunming [Auteur]
Savoirs, Textes, Langage (STL) - UMR 8163 [STL]
Lee, Simon M. Y. [Auteur]
Wang, Ruibing [Auteur]
Journal title :
Organic & Biomolecular Chemistry
Pages :
8046--8053
Publisher :
Royal Society of Chemistry
Publication date :
2017-10
ISSN :
1477-0520
English keyword(s) :
angiogenesis
bioavailability
cancer
complexation
drug
encapsulation
Hepatotoxicity
sorafenib
synthetic receptor
zebrafish
bioavailability
cancer
complexation
drug
encapsulation
Hepatotoxicity
sorafenib
synthetic receptor
zebrafish
HAL domain(s) :
Chimie
English abstract : [en]
Small-molecule kinase inhibitors (SMKIs) have been widely used in the treatment of a variety of cancers due to their clinically demonstrated efficacy. However, the use of some SMKIs, such as sorafenib (SO), has been plagued ...
Show more >Small-molecule kinase inhibitors (SMKIs) have been widely used in the treatment of a variety of cancers due to their clinically demonstrated efficacy. However, the use of some SMKIs, such as sorafenib (SO), has been plagued by their cardiotoxicity that has been frequently observed in treated patients. Herein we report that the encapsulation of SO by a synthetic receptor cucurbit[7]uril (CB[7]) alleviated the inherent cardiotoxicity of SO, as demonstrated in an in vivo zebrafish model. Moreover, the anti-cancer activity of SO was well preserved, upon its encapsulation by CB[7], as demonstrated by both in vitro and in vivo cancer/angiogenesis models. This discovery may provide new insights into a novel supramolecular formulation of SMKIs for the management of their side-effects.Show less >
Show more >Small-molecule kinase inhibitors (SMKIs) have been widely used in the treatment of a variety of cancers due to their clinically demonstrated efficacy. However, the use of some SMKIs, such as sorafenib (SO), has been plagued by their cardiotoxicity that has been frequently observed in treated patients. Herein we report that the encapsulation of SO by a synthetic receptor cucurbit[7]uril (CB[7]) alleviated the inherent cardiotoxicity of SO, as demonstrated in an in vivo zebrafish model. Moreover, the anti-cancer activity of SO was well preserved, upon its encapsulation by CB[7], as demonstrated by both in vitro and in vivo cancer/angiogenesis models. This discovery may provide new insights into a novel supramolecular formulation of SMKIs for the management of their side-effects.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Collections :
Source :